МОДИФИЦИРОВАННЫЙ ФАКТОР VII

Изобретение относится к медицине, а именно к способам лечения, касающимся улучшения регионального миокардиального кровотока в процессе постишемической реперфузии, а также предупреждения или минимизации повреждений ткани, связанных с постишемической перфузией. Указанное назначение осуществляется путем введения пациенту композиции, которая содержит фармакологически приемлемый Фактор VII, имеющий в своем каталитическом центре по меньшей мере одну модификацию, которая существенно ингибирует способность модифицированного Фактора VII активировать плазменный Фактор Х или IX. Использование Фактора VII, модифицированного указанным образом, позволяет повысить эффективность лечения. 4 с. и 14 з.п. ф-лы, 22 табл., 11 ил.

Способ получения белковых компонентовКРОВи

EINKOMPONENTEN-GEWEBEKLEBER SOWIE VERFAHREN ZU SEINER HERSTELLUNG

KOLLAGENE WUNDAUFLAGE

PROTEIN C DERIVATE

VERFAHREN ZUM PASTEURISIEREN VON PLASMAPROTEIN UND PLASMAPROTEINFRAKTIONEN

PREVENTION UND BEHANDLUNG ISCHEMISCHER VORFÄLLE UND HIERAUS RESULTIERENDER PERFUSIONSVERLETZUNGEN

PROCEDURE FOR THE PRODUCTION OF AN ANTI-SERUM FOR THE QUANTITATIVE REGULATION OF HIGH-MOLECULAR DISMANTLING PRODUCTS OF THE FIBRINS AND FIBRINOGENS

PROCEDURE FOR THE PRODUCTION OF BLOOD COAGULATE-PROMOTING PRAEPERATION FROM HUMAN BLOOD PLASMA

PREVENTION UND BEHANDLUNG ISCHEMISCHER VORFÄLLE UND HIERAUS RESULTIERENDER PERFUSIONSVERLETZUNGEN

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND WUNDABDECKUNG.

PROCEDURE FOR THE PRODUCTION OF THE THERAPEUTICALLY USABLE ONE FVIII/VWF COMPLEX AND RESULTING PRODUCTS.

PROCEDURE FOR THE PRODUCTION OF GERM-FREE ONES PROTEIN MIXTURES.

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND CICATRISATION.

PLASMA AND FORMULATIONS OF RECOMBINATION PROTEIN IN AN ENVIRONMENT OF LOW ION STRENGTH.

LYS PLASMINOGEN IN PREVENTING AND TREATMENT OF ISCHÄMIE AND REPERFUSIONSCHÄDEN

PROCEDURE FOR THE PRODUCTION OF AN ANTI-SERUM FOR THE QUANTITATIVE REGULATION OF HIGH-MOLECULAR DISMANTLING PRODUCTS OF THE FIBRINS AND FIBRINOGENS

FABRIC ADHESIVE.

PHARMACEUTICAL COMPOSITIONS CONTAINING FACTOR VIII AND NEUTRAL ONE LIPOSOMEN

USE FROM ACTIVATED PROTEIN C TO THE TREATMENT OF EXCEEDING BLOOD CLOTTING WITH SEPSES

BLOOD FRACTIONATION PROCESS

Factor VII or VIIa-like molecules

Bioresorbable polymeric clayey and sticky substance

COLLAGEN AND OR FABRINOGEN AS CARRIER OF DRUGS FOR THEIR INTRODUCTION INTO CELLULAR LESION AREAS

METHOD FOR CONTROLLING BLEEDING

Factor VIII:C deficiency in a hemophilic mammal may be bypassed by infusion of a synergistic mixture of a phospholipid and Factor Xa so that the cascade process of blood clotting may continue. The proportions of phospholipid and Factor Xa in the mixture are critical as too little Xa has no effect while too much is toxic (thrombogenic). Infusion of the phosphilipid-Factor Xa mixture into normal mammals enhances the natural clotting rate and provides a method for rapidly controlling bleeding in emergency situations.

PROCESS FOR PRODUCING A STABLE PLASMA PROTEIN FREE FROM HYPOTENSIVE SUBSTANCE

METHOD OF SEPARATING A FACTOR IX PREPARATION FROM PLASMA

PARTIALLY DEMINERALIZED CORTICAL BONE CONSTRUCTS

The invention is directed toward a sterile bone structure for application to a bone defect site to promote new bone growth at the site comprising a partially demineralized cortical bone structure, said bone structure comprising a cross sectional surface are ranging from 85% to 95% of the original bone surface area before demineralization with the remaining partially demineralized cortical bone structure having an outer demineralized layer ranging in thickness from about 0.05 mm to about 0.14mm and a mineralized core.

CATIONIC ALKYD POLYESTERS FOR MEDICAL APPLICATIONS

The present invention is directed to medical devices or pharmaceutical compositions, each containing a synthetic, biodegradable, biocompatible polymer that is the reaction product of a polybasic acid or derivative thereof, a monoglyceride and a cationic polyol.

PREVENTION AND TREATMENT OF ISCHEMIC EVENTS AND REPERFUSION INJURY RESULTING THEREFROM

A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. the administration of lys-plasminogen can used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like.

ACTIVATED FACTOR VIII AS A THERAPEUTIC AGENT AND METHOD OF TREATING FACTOR VIII DEFICIENCY

Stabilized and activated Factor VIII is used as a therapeutic agent to treat patients with a Factor VIII deficiency. This includes hemophilia A patients as well as patients with Factor VIII inhibitors which block the hemostatic activity of Factor VIII. The stabilized and activated Factor VIII is also prepared in a therapeutic composition with a therapeutically acceptable adjuvant.

USE OF CELL MEMBRANE PERMEANTS IN THE TREATMENT OF CELLULAR PROLIFERATIVE DISEASES

Methods are provided for the treatment of a host suffering from a cellular proliferative disease through administration of a chemotherapeutic agent in conjunction with a cell membrane permeant. Optionally, the cell membrane permeant and/or chemotherapeutic agent will be present in a pharmaceutically acceptable vehicle capable of acting as a depot. In the subject methods, the chemotherapeutic agent and membrane permeant are administered at least proximal to a target site of the host. Administration of chemotherapeutic agents in accordance with the subject methods results in improved efficacy of, and/or decreased host toxicity to, the intralesionally administered chemotherapeutic agent.

Verfahren zur Herstellung von Trägern für Arzneimittel.

PROCEDURE FOR THE PRODUCTION OF AN INTERLACED WATER-INSOLUBLE OF HAPTOGLOBINPRAEPARATES.

PROCEDURE FOR THE PRODUCTION OF AN ANTI-SERUM FOR THE QUANTITATIVE REGULATION OF HIGH-MOLECULAR DISMANTLING PRODUCTS OF THE FIBRINS AND FIBRINOGENS.

PROCEDURE FOR THE PRODUCTION A BLUTGERINNUNGSFOERDERNDEN OF A PREPARATION FROM HUMAN BLOOD PLASMA.

DRUG FOR THE TREATMENT OF TO INCREASING FIBRINOGENGEHALT IN THE BLOOD PLASMA FUEHRENDEN PATHOLOGICAL PROCESSES.

NASALE PHARMACEUTICAL COMPOSITIONS.

СПОСІБ ЛІКУВАННЯ ГІПЕРКОАГУЛЯЦІЙНИХ СТАНІВ НАДБАНОГО ДЕФІЦИТУ ПРОТЕЇНУ C

Винахід відноситься до медицини, описує спосіб лікування пацієнтів-людей зі станом набутої гіперкоагуляції або набутої недостатності білка С, що пов'язані з сепсисом, блискавичною пурпурою, менінгококовим сепсисом, пересадженням кісткового мозку та інших органів, тяжкими опіками, вагітністю, великим оперативним втручанням, тяжкою травмою або респіраторним дистрес-синдромом у дорослих, який включає введення активованого білка С.

MODIFIED FACTOR VII

MODIFIED PORCINE FACTOR VIII AND ITS THERAPEUTIC USE

MANUFACTORING PROCESS Of a PREPARATION SUPPORTING the COAGULATION OF BLOOD FROM HUMAN BLOOD PLASMA

METHOD FOR OBTAINING THE COMPLEX FVIII/VWF OF THERAPEUTIC USE AND PRODUCTS PRODUCED THEREBY

MODIFIED FACTOR VIII

PROTEIN C DERIVATIVES

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

Rapidly solubilized AHF composition and process for preparing same

The rate of solubility of a freeze-dried solid composition containing therapeutic amounts of anti-hemophilic factor (AHF) is greatly increased by carrying out the solubilization in the presence of at least a critical threshold amount of a water soluble carbohydrate. The carbohydrate is incorporated into the AHF composition in sufficient quantity to provide at least 2 weight units of carbohydrate (expressed in grams) per 100 volume units of AHF solution (expressed in milliliters). This enhanced rate of solubility permits rapid treatment of hemophilic patients.

Method of reendothelializing vascular linings

A method for treating the vascular passage of a patient, damaged by procedures such as an endarterectomy which denude portions of the vascular passages of their endothelial cell linings, is disclosed. In this method, endothelial cells are isolated from the patient's own microvessels, the flow of blood through the patient's damaged vascular passage is interrupted, the endothelial cells isolated from the patient's microvessels are applied to the surface of the denuded portion of the patient's vascular passage in a density sufficient to provide covereage of at least about 50% of said denuded portion, and interruption of blood flow through the vascular passage is maintained for a period of time sufficient to allow the sodded cells to form an attachment to the vascular lining sufficient to withstand the shear created by resumed blood flow through the vascular passage.

DNA-construct for the tissue-specific expression of a blood coagulation factor

Enriched plasma derivative for promoting wound sealing and wound healing

Enriched plasma deriv. (A) comprises components exclusively in powdered form and its compsn. is chosen with regard (a) to optimal activation of exogenous and/or endogenous blood coagulation systems and (b) to a number of physiological and opt. pathological considerations. The major components are fibrinogen (I), thrombin (II), components of the prothrombin (III) complex and protease inhibitors. It may also contain thrombocyte extracts, antibiotics, etc. A pref. formulation contains 60-96 wt.% (I), practically free of water-insoluble globulins (content pref. below 2 wt.%); 0.05-5 wt.% fibrinolysis inhibitors; 0.1-15 wt.% (II) and/or (III). All components are in solid, powdered forms and are simply mixed together. (A) is a biochemical substrate for accelerating haemostasis and optimal regulation of wound closure. It has an almost unlimited storage life at room temp. without agglomeration; can be used directly without any additives, and is quickly soluble in body fluids.

Pharmaceutical preparation containing a thrombolytically active substance and Protein C

The invention relates to a pharmaceutical preparation containing a substance which has thrombolytic activity and does not activate protein C, and containing protein C. This preparation prevents reocclusion which normally occurs in thrombolysis therapy.

Plasma and recombinant protein formulations in low ionic strength media

СПОСОБ ПРЕДОТВРАЩЕНИЯ И ЛЕЧЕНИЯ ИШЕМИЧЕСКИХ ПРИСТУПОВ И ВОЗНИКАЮЩЕГО ОТ НИХ РЕПЕРФУЗИОННОГО ПОВРЕЖДЕНИЯ

Обнаружено, что лиз-плазминоген, который может быть получен посредством протеолитического расщепления глу-плазминогена, оказывает защитное действие на ткань, которая была повреждена при ишемическом состоянии. Введение лиз-плазминогена может использоваться для лечения пациентов во время реперфузии и после того, как реперфузия произошла. Лиз-плазминоген также может быть назначен в сочетании с терапией разложения тромба, такой как те, в которых применяются активатор ткани плазминогена и тому подобные.

1-(ARYL-OR HETEROARYL)OXY-3-(SUBSTITUTED-AMINO)PROPAN-2-OL DERIVATIVES PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

... 1509527 1 - Aryl or heteroaryloxy - 3- substituted amino propan-2-ols, their preparation and their pharmaceutical compositions IMPERIAL CHEMICAL INDUSTRIES Ltd 28 May 1975 [5 June 1974] 24837/74 Addition to 1455116 Heading C2C The invention comprises compounds of the general Formula (I) wherein A represents a C 2-12 alkylene group; X represents a carbonyl or sulphonyl group; Y represents a direct bond or C 1-6 alkylene, C 1-6 oxyalkylene, C 1-6 alkyleneoxy, imino, C 1-6 alkylimino, C 1-6 iminoalkylene, C 1-6 iminoalkylenoxy or C 1-6 iminoalkylenecarbonyloxy radical or, when R1 is other than hydrogen, an oxygen atom and either (a), R represents an optionally substituted heterocyclic ring system or an aryl radical of Formula (Ia) and R1 represents an optionally substituted heterocylic ring system or an aryl radical of Formula (Ib) wherein R2, R3, R12 and R13 are independently a H or halogen atom or an OH, NH 2 , NO 2 , CN, C 1-6 alkyl, ...

DISTANCE OF FAT-SOLUBLE REAGENTS FROM BIOLOGICAL MATERIALS BY EXTRACTING WITH NATURAL OILS OR SYNTHETIC ERSÄTZEN OF IT

VERFAHREN ZUM PASTEURISIEREN VON PLASMAPROTEIN UND PLASMAPROTEINFRAKTIONEN

PROTEIN C OF DERIVATIVES

PROCEDURE FOR THE PRODUCTION OF VITAMIN K DEPENDENT PROTEINS

COAGULATING FACTOR VII OR VIIA KONJUGATE

VERFAHREN ZUR HERSTELLUNG EINES ANTISERUMS ZUR QUANTITATIVEN BESTIMMUNG VON HOCHMOLEKULAREN ABBAUPRODUKTEN DES FIBRINS UND FIBRINOGENS

PROCEDURE FOR THE PRODUCTION OF A BONE CEMENT

KOLLAGENE WUNDAUFLAGE.

SINGLE COMPONENT FABRIC ADHESIVE AS WELL AS PROCEDURE FOR ITS PRODUCTION.

THROMBIN COMPOSITION FOR ORAL ADMINISTRATION.

KATIONISCHE ALKID POLYESTER FOR MEDICAL APPLICATIONS

CONTROLLING OF THE HEALING PROCESS

STREPTOKINASE/PLASMINOGEN BINARY COMPLEX

Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency

ICALS

POLYSUCCINIMIDES AND COMPLEXES WITH PROTEINS

Mutant human factor ix with an increased resistance to inhibition by heparin

Partially demineralized cortical bone constructs

STREPTOKINASE/PLASMINOGEN BINARY COMPLEX

BLOOD COAGULATION COMPLEX

ONE-COMPONENT TISSUE ADHESIVE AND A PROCESS FOR THE PRODUCTION THEREOF

... of the disclosure A description is given of a one-component tissue adhesive containing, in aqueous solution, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor and of a process for the production thereof. This adhesive can be reconstituted from a freeze-dried form with water. It can contain all active substances in pasteurized form and is then free of the risk of transmission of hepatitis and HTLV III.

PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VIII AND NEUTRAL LIPOSOMES

A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and substantially neutral colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer which carries substantially no net charge. The protein or polypeptide is capable of externally binding the colloidal particles, or is capable of binding polyethylene glycol, and is not encapsulated in the colloidal particles. A preferred protein is factor VIII, whose half-life is extended and which is protected from serum inhibitor antibodies by injecting it as a component of the composition.

CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIB/IIIA

... 2148945 9411398 PCTABS00032 This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation.

СПОСОБЫ ЛЕЧЕНИЯ СОСТОЯНИЙ ГИПЕРКОАГУЛЯЦИИ ИЛИ ПРИОБРЕТЕННОЙ НЕДОСТАТОЧНОСТИ БЕЛКА С

... 1. Способ лечения больных людей с приобретенным состоянием гиперкоагуляции или приобретенной недостаточностью белка С, который включает введение указанному пациенту с помощью постоянного вливания в течение от приблизительно 24 до приблизительно 144 ч активированного белка С человека в дозировке от приблизительно 20 до приблизительно 50 мкг/кг/ч. 2. Способ по п.1, в котором указанное состояние гиперкоагуляции или недостаточность белка С связаны с сепсисом. 3. Способ по п.1, в котором указанное состояние гиперкоагуляции или недостаточность белка С связаны со скоротечной пурпурой. 4. Способ по п.1, в котором указанное состояние гиперкоагуляции или недостаточность белка С связаны с менингококкемией. 5. Способ по п.4, в котором больной человек является подростком. 6. Способ по п.1, в котором указанное состояние гиперкоагуляции или недостаточность белка С связаны с ожогами. 7. Способ по п.1, в котором указанный способ лечения предназначен для людей, страдающих венозными тромбоэмболическими осложнениями ...

METHODS FOR TREATMENT OF HYPERCOAGULATION STATE OR ACQUIRED PROTEIN INSUFFICIENCY OF C

NEW SULPHATES OF XYLANS, THEIR METHOD OF PREPARATION AND THEIR ACTIVITY ANTI-THROMBOTIQUE AND HYPOLIPEMIANTE

NEW SULPHATES OF XYLANS, THEIR METHOD OF PREPARATION AND THEIR ACTIVITY ANTI-THROMBOTIQUE AND HYPOLIPEMIANTE

SETT ATT FRAMSTELLA EN ANTIHEMOFILIFAKTOR

PROTEIN C DERIVATIVES

Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity and resistance to inactivation by serpins compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute coronary syndromes, vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

PROCESS FOR THE SURFACE MODIFICATION OF A POLYMER SUBSTRATE AND POLYMERS FORMED THEREFROM

A process for forming a surface modification on a polymer substrate and polymer substrates having such surface modifications. The process comprises the steps of: absorbing a swelling monomer into the polymer substrate for a period of time in order to swell the polymer substrate; removing the swollen polymer from the swelling monomer; transferring the swollen polymer to a reaction mixture containing at least one functional monomer; polymerizing the functional monomer in the reaction mixture containing the swollen polymer substrate for a period of time; and removing the polymer from the reaction mixture. Because the surface modification produced by the process is a surface interpenetrating polymer network, the process is not sensitive to the reactive groups located on the surface of the polymer substrate. Further, the surface interpenetrating network bonds to the polymer substrate through caternary connections or other forms of chain entanglement and thus is quite stable. Polymer substrates ...

METHOD FOR MAKING IMPROVED HEPARINIZED BIOMATERIALS

A method of making a medical device having immobilized heparin on a blood-contacting surface in which the covalently attached heparinized surface is provided with an adsorbed protein which may be activated by the immobilized heparin to block the coagulation of fibrinogen. Antithrombin III is the preferred adsorbed protein. The adsorbed protein is maintained on the immobilized heparin surface until the medical device is placed into contact with the patient's blood. When in contact with the patient's blood, the adsorbed protein will prevent initial thrombin formation at the biomaterial-blood interface. The preadsorption of ATIII is accomplished under conditions advantageous to maximum heparin/ATIII binding. When the preadsorbed surface comes in contact with whole blood, the maximum advantage of prophylactic properties of ATIII/heparin are obtained.

Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma

This invention concerns a method of preparing a cryoprecipitated suspension containing fibrinogen and Factor XIII useful as a precursor in the preparation of a fibrin glue which involves (a) freezing fresh frozen plasma from a single donor such as a human or other animal, e.g. a cow, sheep or pig, which has been screened for blood transmitted diseases, e.g. one or more of syphilis, hepatitis or acquired immune deficiency syndrome at about =80° C. for at least about 6 hours, preferably for at least about 12 hours; (b) raising the temperature of the frozen plasma, e.g. to between about 0° C. and room temperature, so as to form a supernatant and a cryoprecipitated suspension containing fibrinogen and Factor XIII; and (c) recovering the cryoprecipitated suspension. The invention also concerns a method of preparing a fibrin glue useful in surgical procedures which comprises: (a) preparing a cryoprecipitated suspension as described above; (b) applying a defined volume of the suspension to a desired ...

Fibrinogen peptide derivatives

Fibrinogen peptide derivatives which have biological activity as anticoagulants of blood having the dipeptide moiety prolylarginine or the tripeptide moiety glycylprolylarginine, e.g., L-prolyl-L-arginine benzyl ester p-toluenesulfonate trifluoroacetate, glycyl-L-prolyl-L-arginine benzyl ester p-toluenesulfonate trifluoroacetate, N-t-butyloxycarbonyl-L-prolyl-L-arginine benzyl ester p-toluenesulfonate methanolate, N-benzyloxycarbonyl-prolyl-L-arginine benzyl ester p-toluenesulfonate methanolate and N-t-butyloxycarbonylglycol-L-prolyl-L-arginine benzyl ester p-toluenesulfonate.

Factor VIII polypeptide

The application discloses Factor VIII polypeptides comprising internal deletions of amino acids within the area of residues 741 to 1689, wherein the thrombin cleavage sites at about 741 and about 1689 are present, and a site at about 1648 is not present, as compared to human Factor VIII.

Antihemophilic factor concentrate and its production

Antihemophilic factor (AHF) concentrate having enhanced potency and solubility and its process of production are provided. The process includes the steps of removing unwanted protein from an aqueous extract of antihemophilic blood plasma cryoprecipitate by mixing the aqueous extract with aluminum hydroxide at an acid pH in the cold, adjusting the purified aqueous extract to an acid pH and freeze-drying the extract, optionally removing water from the extract just before freeze-drying.

Factor VII or VIIa-like molecules

Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Medicaments for the suppression of pathological processes

The increase in concentration of one or several plasma-proteins in the blood is specific for various pathological processes, especially inflammations. A medicament which in a typical way, exactly contains increasingly available plasma-proteins for a pathological process, attenuates the progress of the pathological process, as by this means, the defence system of the body itself is strengthened, which reacts in a specific way on such pathological processes, with the increased formation of one or several plasma-proteins specific for this. This effect is especially demonstrated in regard to Fibrinogen. It demonstrates further that the effect of the Fibrinogen is thereupon to be traced back in that, in regard to reaction with Thrombin at the point of the inflammation, the fibrinopeptides A and B are formed.

Alkanolamine derivatives

Novel 1-heterocyclyloxy- or 1-aryloxy-3-amido-alkylamino-2-propanol derivatives, processes for their manufacture, pharmaceutical compositions containing them and methods of using them in the treatment of heart diseases. The compounds possess beta -adrenergic blocking activity. Representative of the compounds disclosed is 1-(4-indolyloxy)-3- beta -isobutyramidoethylamino-2-propanol.

CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa

This invention relates to novel cyclic compounds linked by a heterocyclic ring system, which are useful as antagonists of the platelet glycoprotein IIb/IIIa complex, to pharmaceutical compositions containing such cyclic compounds, and to methods of using these compounds for the inhibition of platelet aggregation.

Lys-Plasminogen in der Verhütung und Behandlung von Ischämie und Reperfusionschäden

VERFAHREN ZUR HERSTELLUNG VITAMIN-K-ABHÄNGIGER PROTEINE

FAKTOR VIII ODER VON WILLEBRAND FAKTOR ZUR BEHANDLUNG VON THROMBOPATHIE ASSOZIIERENDEN HÄMORRHAGISCHEN ERKRANKUNGEN

Procedure for the production of a sturdy and of hypotensiven materials free plasma protein

Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation

본 출원은 일반적으로 이를 필요로 하는 개체에서 출혈 및/또는 응고성 저하를 예방하거나 치료하기 위한 방법, 및 이러한 방법에 사용하기 위한 조성물에 관한 것이다. 상기 방법은 FVa, 바람직하게는 APC 내성 FVa(예를 들면, 수퍼FVa)를 단독으로 또는 FVIIa, 바람직하게는 rhFVIIa(예를 들면, NovoSeven® 또는 향상된 활성 또는 반감기를 갖는 다른 FVIIa)와 조합하여 투여함을 포함한다. 조합하여 투여된 경우, FVa 및 FVIIa는 이를 필요로 하는 대상체, 예를 들면, 혈우병과 같은 유전 장애 또는 후천적 출혈 장애 또는 출혈성 뇌졸중 또는 쇼크, 외상, 수술 또는 월경 곤란증과 같은 출혈 또는 응고성 저하와 관련된 다른 상태를 갖는 대상체 또는 FVIII 또는 FIX와 같은 응고촉진제에 대한 억제 항체를 생성하거나 직접 Xa 또는 직접 트롬빈 억제제 또는 신규한 경구 항응고제(NOAC)와 같은 항응고 약물의 과용량을 투여했거나 원인 불명 출혈을 입증한 개체에서 출혈 또는 응고성 저하를 치료하거나 예방하기 위해 사용될 때 상승작용적 이점을 유도한다. 또한, 본 발명은, 예를 들면, APC 과생산(예를 들면, 중증 손상 및/또는 출혈성 쇼크를 통해) 또는 APC 또는 다른 항응고제 요법의 결과로, APC-관련 출혈을 예방하고, 치료하거나 역전시키기 위해, 예를 들면, 염증성 장애 또는 패혈증 질환을 치료하는데 수퍼FVa의 단독 또는 FVIIa 또는 다른 응고촉진제 또는 프로-지혈제와의 병용 사용에 관한 것이다.